These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 28888210)

  • 41. Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells.
    Xu XJ; Tang YM
    Cancer Lett; 2014 Feb; 343(2):172-8. PubMed ID: 24141191
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Construction, expression, and characterization of anticarcinoma sFv fused to IL-2 or GM-CSF.
    Zhao L; Rai SK; Grosmaire LS; Ledbetter JA; Fell HP
    J Hematother Stem Cell Res; 1999 Aug; 8(4):393-9. PubMed ID: 10634177
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bispecific antibodies for cancer therapy.
    Hollander N
    Immunotherapy; 2009 Mar; 1(2):211-22. PubMed ID: 20635943
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cytokine gene-engineered vaccines.
    Forni G; Boggio K
    Curr Opin Mol Ther; 1999 Feb; 1(1):34-8. PubMed ID: 11249681
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antibody targeted drugs as cancer therapeutics.
    Schrama D; Reisfeld RA; Becker JC
    Nat Rev Drug Discov; 2006 Feb; 5(2):147-59. PubMed ID: 16424916
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development of antibodies and chimeric molecules for cancer immunotherapy.
    Waldmann TA; Morris JC
    Adv Immunol; 2006; 90():83-131. PubMed ID: 16730262
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antibody-Based Cancer Therapy: Successful Agents and Novel Approaches.
    Hendriks D; Choi G; de Bruyn M; Wiersma VR; Bremer E
    Int Rev Cell Mol Biol; 2017; 331():289-383. PubMed ID: 28325214
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The dose-dependent tumor targeting of antibody-IFNγ fusion proteins reveals an unexpected receptor-trapping mechanism in vivo.
    Hemmerle T; Neri D
    Cancer Immunol Res; 2014 Jun; 2(6):559-67. PubMed ID: 24795141
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cytokine therapy for cancer.
    Tagawa M
    Curr Pharm Des; 2000 Apr; 6(6):681-99. PubMed ID: 10788604
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma.
    Chmielewski M; Hombach AA; Abken H
    Immunol Rev; 2014 Jan; 257(1):83-90. PubMed ID: 24329791
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A novel antibody-4-1BBL fusion protein for targeted costimulation in cancer immunotherapy.
    Müller D; Frey K; Kontermann RE
    J Immunother; 2008 Oct; 31(8):714-22. PubMed ID: 18779748
    [TBL] [Abstract][Full Text] [Related]  

  • 52. IL4-10 Fusion Protein Is a Novel Drug to Treat Persistent Inflammatory Pain.
    Eijkelkamp N; Steen-Louws C; Hartgring SA; Willemen HL; Prado J; Lafeber FP; Heijnen CJ; Hack CE; van Roon JA; Kavelaars A
    J Neurosci; 2016 Jul; 36(28):7353-63. PubMed ID: 27413147
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeting of IL-2 and GM-CSF immunocytokines to a tumor vaccine leads to increased anti-tumor activity.
    Fournier P; Aigner M; Schirrmacher V
    Int J Oncol; 2011 Jun; 38(6):1719-29. PubMed ID: 21424118
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT).
    Biela BH; Khawli LA; Hu P; Epstein AL
    Cancer Biother Radiopharm; 2003 Jun; 18(3):339-53. PubMed ID: 12954121
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fighting cancers from within: augmenting tumor immunity with cytokine therapy.
    Pellegrini M; Mak TW; Ohashi PS
    Trends Pharmacol Sci; 2010 Aug; 31(8):356-63. PubMed ID: 20561689
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Antitumor effects of cytokines with immunomodulatory activity].
    Radzikowski C; Pajtasz-Piasecka E; Glazman-Kuśnierczyk H
    Acta Haematol Pol; 1994; 25(2 Suppl 1):32-40. PubMed ID: 8067205
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation.
    Frey K; Zivanovic A; Schwager K; Neri D
    Integr Biol (Camb); 2011 Apr; 3(4):468-78. PubMed ID: 21225052
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genetically marking human cells--results of the first clinical gene transfer studies.
    Cai Q; Rubin JT; Lotze MT
    Cancer Gene Ther; 1995 Jun; 2(2):125-36. PubMed ID: 7621260
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 60. B7.1/NHS76: a new costimulator fusion protein for the immunotherapy of solid tumors.
    Liu A; Hu P; Khawli LA; Epstein AL
    J Immunother; 2006; 29(4):425-35. PubMed ID: 16799338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.